MX2020012760A - Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2. - Google Patents

Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2.

Info

Publication number
MX2020012760A
MX2020012760A MX2020012760A MX2020012760A MX2020012760A MX 2020012760 A MX2020012760 A MX 2020012760A MX 2020012760 A MX2020012760 A MX 2020012760A MX 2020012760 A MX2020012760 A MX 2020012760A MX 2020012760 A MX2020012760 A MX 2020012760A
Authority
MX
Mexico
Prior art keywords
inhibitors
cannabinoid receptor
pyrazine compounds
novel pyridine
sup
Prior art date
Application number
MX2020012760A
Other languages
English (en)
Inventor
Luca Gobbi
Uwe Grether
Simon M Ametamey
Julian Kretz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020012760A publication Critical patent/MX2020012760A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere a un compuesto de fórmula (I) (ver Fórmula) en donde A1, A2, X y R1-R3 son como se definen en la descripción y en las reivindicaciones. El compuesto de fórmula (I) puede usarse como un medicamento, debido a su inhibición de receptor cannabinoide 2.
MX2020012760A 2018-06-27 2019-06-25 Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2. MX2020012760A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18180137 2018-06-27
PCT/EP2019/066811 WO2020002320A1 (en) 2018-06-27 2019-06-25 Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2

Publications (1)

Publication Number Publication Date
MX2020012760A true MX2020012760A (es) 2021-03-25

Family

ID=62814868

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012760A MX2020012760A (es) 2018-06-27 2019-06-25 Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2.

Country Status (18)

Country Link
US (1) US20210115011A1 (es)
EP (1) EP3814329B1 (es)
JP (1) JP7445610B2 (es)
KR (1) KR20210028202A (es)
CN (1) CN112262132A (es)
AU (1) AU2019294256B2 (es)
BR (1) BR112020025013A2 (es)
CA (1) CA3096777A1 (es)
CL (1) CL2020003331A1 (es)
CO (1) CO2020011855A2 (es)
CR (1) CR20200643A (es)
IL (1) IL279725B2 (es)
MA (1) MA53002A (es)
MX (1) MX2020012760A (es)
PE (1) PE20210368A1 (es)
PH (1) PH12020552152A1 (es)
SG (1) SG11202009103WA (es)
WO (1) WO2020002320A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018234284A1 (en) 2017-06-20 2018-12-27 F. Hoffmann-La Roche Ag PYRIDINE DERIVATIVES
CN112638430B (zh) 2018-06-27 2023-05-16 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
WO2020002270A1 (en) 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
CA3235177A1 (en) 2021-10-28 2023-05-04 Genentech, Inc. Systems and methods to identify mhc-associated antigens for therapeutic intervention

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
JP2007523206A (ja) * 2004-02-24 2007-08-16 グラクソ　グループ　リミテッド Ｃｂ２受容体モジュレーターとしてのピリジン誘導体およびその使用
WO2006105217A2 (en) 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
FR2887550A1 (fr) 2005-06-24 2006-12-29 Sanofi Aventis Sa Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique
ES2344128T3 (es) * 2006-10-04 2010-08-18 F. Hoffmann-La Roche Ag Derivados de pirazina-2-carboxamida como moduladores de receptores cb2.
EP2311443A1 (en) 2009-10-15 2011-04-20 Rheinische Friedrich-Wilhelms-Universität Pharmaceutical composition containing cannabinoid-receptor 2 antagonists
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives
LT2928882T (lt) * 2012-12-07 2017-03-27 F. Hoffmann-La Roche Ag Pirazino dariniai kaip cb2 receptoriaus agonistai
LT2928868T (lt) * 2012-12-07 2017-10-25 F. Hoffmann-La Roche Ag Piridin-2-amidai, tinkami naudoti kaip cb2 agonistai
PE20161407A1 (es) * 2014-04-04 2016-12-28 Hoffmann La Roche Piridina 5,6 disustituida -2-carboxamidas como agonistas del receptor canabinoide
SG11201608108SA (en) * 2014-04-04 2016-10-28 Hoffmann La Roche Pyridine-2-amides useful as cb2 agonists

Also Published As

Publication number Publication date
BR112020025013A2 (pt) 2021-03-23
EP3814329B1 (en) 2024-01-17
AU2019294256B2 (en) 2024-06-20
US20210115011A1 (en) 2021-04-22
PE20210368A1 (es) 2021-02-26
CA3096777A1 (en) 2020-02-02
JP7445610B2 (ja) 2024-03-07
JP2021529157A (ja) 2021-10-28
SG11202009103WA (en) 2020-10-29
IL279725B1 (en) 2023-12-01
MA53002A (fr) 2021-05-05
EP3814329A1 (en) 2021-05-05
CL2020003331A1 (es) 2021-05-07
KR20210028202A (ko) 2021-03-11
CN112262132A (zh) 2021-01-22
IL279725B2 (en) 2024-04-01
EP3814329C0 (en) 2024-01-17
AU2019294256A1 (en) 2020-09-24
IL279725A (en) 2021-03-01
WO2020002320A1 (en) 2020-01-02
PH12020552152A1 (en) 2021-07-05
CO2020011855A2 (es) 2020-10-20
CR20200643A (es) 2021-05-11

Similar Documents

Publication Publication Date Title
MX2020012760A (es) Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2.
MX2021000795A (es) Compuestos heterociclicos para inhibir la actividad de shp2.
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
GEP20207111B (en) Heteroaryl compounds for kinase inhibition
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
AU2018274723A1 (en) Benzimidazolone derived inhibitors of BCL6
EP4001273A3 (en) Aminopyrimidines as alk inhibitors
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2016016528A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2021004659A (es) Derivados de aminopirimidina/pirazina como inhibidores de ctps1.
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
MX2020002449A (es) Nuevos compuestos heterociclicos fungicidas.
MX2022006711A (es) Nuevos inhibidores de braf como rompedores de la paradoja.
MX2021003427A (es) Nuevos oxadiazoles.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
SG10201809066TA (en) 5,6-Disubstituted Pyridine-2-Carboxamides and 5,6-Disubstituted Pyrazine-2-Carboxamides as Cannabinoid Receptor Agonists
MX2017005422A (es) Inhibidores de histona desacetilasa y sus usos en terapia.